Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)
Clinical trial NCT07730528 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07730528
- Sponsor
- Humacyte, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2030-09-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.